Document Detail

Amiodarone-associated optic neuropathy: a critical review.
MedLine Citation:
PMID:  22385784     Owner:  NLM     Status:  MEDLINE    
Although amiodarone is the most commonly prescribed anti-arrhythmic drug, its use is limited by serious toxicities, including optic neuropathy. Current reports of amiodarone-associated optic neuropathy identified from the Food and Drug Administration's Adverse Event Reporting System and published case reports were reviewed. A total of 296 reports were identified: 214 from the Adverse Event Reporting System, 59 from published case reports, and 23 from adverse events reports for patients enrolled in clinical trials. Mean duration of amiodarone therapy before vision loss was 9 months (range 1-84 months). Insidious onset of amiodarone-associated optic neuropathy (44%) was the most common presentation, and nearly one third were asymptomatic. Optic disk edema was present in 85% of cases. Following drug cessation, 58% had improved visual acuity, 21% were unchanged, and 21% had further decreased visual acuity. Legal blindness (<20/200) was noted in at least one eye in 20% of cases. Close ophthalmologic surveillance of patients during the tenure of amiodarone administration is warranted.
Rod S Passman; Charles L Bennett; Joseph M Purpura; Rashmi Kapur; Lenworth N Johnson; Dennis W Raisch; Dennis P West; Beatrice J Edwards; Steven M Belknap; Dustin B Liebling; Mathew J Fisher; Athena T Samaras; Lisa-Gaye A Jones; Katrina-Marie E Tulas; June M McKoy
Related Documents :
18796144 - A woman living with osteoarthritis: a case report.
372244 - Immunoglobulin and complement in normal skin.
16874424 - Childhood oral mucous membrane pemphigoid presenting as desquamative gingivitis in a 4-...
23119954 - Osteopetrosis-variable otorhinolaryngological manifestations.
23514324 - Peripapillary choroidal neovascularization in pars planitis.
19094914 - Tuberculosis outbreak associated with a mosque: challenges of large scale contact tracing.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2012-03-03
Journal Detail:
Title:  The American journal of medicine     Volume:  125     ISSN:  1555-7162     ISO Abbreviation:  Am. J. Med.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-09     Completed Date:  2012-05-28     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  447-53     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amiodarone / adverse effects*
Anti-Arrhythmia Agents / adverse effects*
Blindness / chemically induced,  etiology
Optic Nerve Diseases / chemically induced*,  complications*,  diagnosis
Grant Support
K01 CA134554-01/CA/NCI NIH HHS; K01 CA134554-01/CA/NCI NIH HHS; K01 CA134554-02/CA/NCI NIH HHS; K01 CA134554-02S1/CA/NCI NIH HHS; K01 CA134554-03/CA/NCI NIH HHS; K23 HL068814/HL/NHLBI NIH HHS; K23 HL068814-01/HL/NHLBI NIH HHS; K23 HL068814-01/HL/NHLBI NIH HHS; P 30 CA60533/CA/NCI NIH HHS
Reg. No./Substance:
0/Anti-Arrhythmia Agents; N3RQ532IUT/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Minimizing inappropriate medications in older populations: a 10-step conceptual framework.
Next Document:  Clinical neuropathology practice news 2-2012: BRAF V600E testing.